Manifestations cutanées des maladies inflammatories de l'intestin
Perles cliniques pour les gastroentérologues
Résumé
Alors que les connaissances des cliniciens sur la relation entre les maladies inflammatoires de l’intestin (MII) et le système tégumentaire continuent de s’approfondir, les gastro-entérologues et les dermatologues doivent connaître les associations de maladies concernées et comprendre l’incidence des traitements sur ces affections immunitaires afin de prendre en charge ces patients présentant des pathologies complexes sur le plan médical.
Références
Elisabetta Antonelli, Gabrio Bassotti, Marta Tramontana, Katharina Hansel, Luca Stingeni, Sandro Ardizzone, Giovanni Genovese, Angelo Valerio Marzano and Giovanni Maconi. Dermatological manifestations in inflammatory bowel disease. Journal of Clinical Medicine. 2021 Jan 19;10(2):364.
Kurtzman DJ, Jones T, Lian F, Peng LS. Metastatic Crohn’s disease: a review and approach to therapy. J Am Acad Dermatol. 2014 Oct;71(4):804-813.
Loredana Ungureanu, Rodica Cosgerea, Mihail Alexandru Badea, Alina Florentina Vasilovici, Iona Cosgerea and Simona Corina Senila. Cutnaeous manifestation sin inflammatory bowel disease. Experimental and Therapeutic Medicine. 2020;20:31-37.
Roth N, Biedermann L, Fournier N, Butter M, Vavricka SR, Navarini AA, Rogler G, Scharl M; Swiss IBD Cohort Study Group. PLoS One. 2019 Jan 25;14(1):e0210436.
Barret M, De Parades V, Battistella M, Sokol H, Lemarchaud N, Marteau P. Crohn’s disease of the vulva. J Crohns Colitis. 2014 Jul;8(7):563-570.
Muhvic-Urek M, Tomac-Stojmenovic M, Mijandrusic-Sincic B. Oral pathology in inflammatory bowel disease. World J Gastroenterol. 2016 Jul 7;22(25):5655-67.
Yüksel I, Başar Ö, Ataseven H, Ertuğrul İ, Arhan M, İbiş M, Dağlı Ü, Demirel BT, Ülker A, Seçilmiş S, Şaşmaz N. Mucocutaneous manifestations in inflammatory bowel disease. Inflammatory Bowel Diseases. 2009 Apr 1;15(4):546-50.
Greuter T, Vavricka SR. Extraintestinal manifestations in inflammatory bowel disease- epidemiology, genetics and pathogenesis. Expert Rev Gastroenterol Hepatol. 2019 Apr;13(4):307-317.
Joshi TP, Friske SK, Hsiou Da, Duvic M. New Practical aspects of Sweet Syndrome. Am J Clin Dermatol. 2022 May;23(3):301-318.
Brown G, Wang E, Leon A, Huynh M, Wehner M, Matro R, Linos E, Liao W, Haemel A. Tumor necrosis factor-α inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience. Journal of the American Academy of Dermatology. 2017 Feb 1;76(2):334-41.
Cottone M, Sapienza C, Macaluso FS, Cannizzaro M. Psoriasis and Inflammatory Bowel Disease. Dig Dis. 2019;37(6):451-457.
Lauritano D, Boccalari E, Stasio D, Della Vella F, Carinci F, Lucchese A, Petruzzi M. Prevalence of Oral lesions and correlation with intestinal symptoms of inflammatory bowel disease: A systematic review. Diagnostics(Basel). 2019 Jul 15;9(3):77.
Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti–tumor necrosis factor biologic therapy: a clinical review. Journal of the American Academy of Dermatology. 2009 Sep 1;61(3):486-504.
Kohorst J, Kimball A, Davis MDP. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015 Nov;73(5 Suppl):S27-35.
Egan CA, Meadows KP, Zone J. Ulcerative colitis and immunobullous disease cured by colectomy. Archives of Dermatology. 1999;135:214-215.
Chen DH, Zhou HR, Zhang YG, Shen GY, Xu C, Guan CL. Drug induced hypersensitivity syndrome induced by sulfasalazine: A case report. Medicine (Baltimore). 2022 Aug 19;101(33):e30060.
McNally A, Ibbetson J, Sidhu S. Azathioprine-induced Sweet’s syndrome: A case series and review of the literature. Australas J Dermatol. 2017 Feb;58(1):53-57.
Romdhane HB, Mokni S, Fathallah N, Slim R, Gharriani N, Sriha B, Ben Salem, C. Sulfasalazine induced sweet’s syndrome. Therapie. 2016 Jun;71(3):345-7.
Azathioprine® Product Monograph, Apotex Inc., Toronto, Ontario. October 28, 2020.
Mesalamine® Product Monograph, Aptalis Pharma Inc., Mont-Saint-Hilaire, Quebec. December 30, 2014.
Hanzel J, Ma C, Casteele NV, Kanna R, Jairath V, Feagan BG. Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease. Drugs. 2021 Feb:81(3):333-347.
Dubinsky M, Cross R, Sandborn W, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Arjit Ganguli, Wang A. Extraintestinal manifestations in vedoluzumab and anti-TNF-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. 2018 Aug 16;24(9):1876 - 1882.
Chateau T, bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L. Vedolizumab treatment in extra-intestinal manifestations in inflammatory bowel disease: A systematic review. J Crohns Colitis. 2019 Dec 10;13(12):1569-1577.
Fleisher M, Marsal J, Lee S, Frado L, Parian A, Korelitz B , Feagan B. Effects of vedolizumab therapy on extraintestinal manifestastions of inflammatory bowel disease. Dig Dis Sci. 2018 Apr;63(4):825-833.
Guedes T, Pedroto I, Lago P. Vedolizumab-associated psoriasis: until where does gut selectivity go? Rev Esp Enferm Dig. 2020 Jul;112(7):580-581.
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian IBD Today 2023
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
